Fig. 7.1
The overall picture of ovarian stimulation protocol: two most commons
Conclusion
Controlled ovarian stimulation is the fundamental program in IVF treatment. Fine-tuning of ovarian stimulation for the purpose of pregnancy with less complication is the main goal of treatment. However, the controversies in the management still exist in the practice today. Randomized controlled studies with enough sample sizes are needed to answer the points that have no conclusions. Poor ovarian response is one of the most challenging tasks in reproductive medicine. Finally, no one ovarian stimulation program for all but each patient needs individualized approach for optimizing the best pregnancy outcomes with the maximum safeness.
References
1.
te Velde E, Pearson P. The variability of female reproductive ageing. Hum Reprod Update. 2002;8:141–54.
2.
Holman DJ, Wood JW, Campbell KL. Age-dependent decline of female fecundity is caused by early fetal loss. In: te Velde ER, Pearson PL, Broekmans FJ, editors. Female reproductive aging. UK: Parthenon Publishing Group; 2000. p. 123–36
3.
Wells D, Delhanty JD. Comprehensive chromosomal analysis of human preimplantation embryos using whole genome amplification and single cell comparative genomic hybridization. Mol Hum Reprod. 2000;6:1055–62.PubMed
4.
Ruess ML, Kline J, Santos R, Levin B, Timor-Tritsch I. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. Am J Obstet Gynecol. 1996;174:624–7.PubMed
5.
Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW, te Velde ER. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril. 1999;72:845–51.PubMed
6.
Tomas C, Nuojua-Huttunen S, Martikainen H. Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotropins in in-vitro fertilization. Hum Reprod. 1997;12:220–3.PubMed
7.
Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril. 1998;69:505–10.PubMed
8.
Haadsma ML, Bukman A, Groen H, Roeloffzen EM, Groenewoud ER, Heineman MJ, Hoek A. The number of small antral follicles (2–6 mm) determines the outcome of endocrine ovarian reserve tests in a subfertile population. Hum Reprod. 2007;22:1925–31.PubMed
9.
Jayaprakasan K, Deb S, Batcha M, Hopkisson J, Johnson I, Campbell B, Raine-Fenning N. The cohort of antral follicles measuring 2–6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Müllerian hormone and response to controlled ovarian stimulation. Fertil Steril. 2010;94:1775–81.PubMed
10.
Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril. 2005;83:291–301.PubMed
11.
Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005;112:1384–90.PubMed
12.
Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.PubMed
13.
Göksedef BP, Idiş N, Görgen H, Asma YR, Api M, Cetin A. The correlation of the antral follicle count and Serum anti-mullerian hormone. J Turk Ger Gynecol Assoc. 2010;11:212–5.PubMedPubMedCentral
14.
Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J. High reproducibility of serum anti- Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod. 2005;20:923–7.PubMed
15.
La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006;21:3103–7.PubMed
16.
Hehenkamp JK, Loomans CW, Themmen AP, de Jong FH, teVelde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;10:4057–63.
17.
Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17:46–54.PubMed
18.
Schipper I, Visser JA, Themmen AP, Laven JS. Limitations and pitfalls of antimullerian hormone measurements. Fertil Steril. 2012;98:823–4.PubMed
19.
Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril. 1989;51:651–4.PubMed
20.
Scott RT Jr, Hofmann GE, Oehninger S, Muasher SJ. Intercycle variability of day 3 follicle- stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. Fertil Steril. 1990;54:297–302.PubMed
21.
Kwee J, Schats R, McDonnell J, Lambalk CB, Schoemaker J. Intercycle variability of ovarian reserve tests: results of a prospective randomized study. Hum Reprod. 2004;19:590–5.PubMed
22.
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718.PubMed
23.
Bancsi LF, Broekmans FJ, Mol BW, Habbema JD, teVelde ER. Performance of basal follicle- stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril. 2003;79:1091–100.PubMed
24.
Esposito MA, Coutifaris C, Barnhart KT. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women. Hum Reprod. 2002;17:118–23.PubMed
25.
Mutlu M, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O, et al. Antral follicle count determines poor ovarian response better than anti-mullerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. J Assist Reprod Genet. 2013;30:657–65.PubMedPubMedCentral
26.
National Institute for Clinical Excellence Guideline. Fertility: assessment and treatment for people with fertility problems. UK: RCOG Press. 2004;60–62. ISBN 1-900364-97-2.
27.
van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril. 2003;80:1086–93.PubMed
28.
Lossl K, Andersen AN, Loft A, et al. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod. 2006;21:2593–600.PubMed
29.
Sullivan MW, Stewart-Akers A, Krasnow JS, et al. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab. 1999;84:228–32.PubMed
30.
Chappel SC, Howles C. Reevaluation of the roles of luteinizing-hormone and follicle-stimulating-hormone in the ovulatory process. Hum Reprod. 1991;6:1206–12.PubMed
31.
Lahoud R, Al-Jefout M, Tyler J, Ryan J, Driscoll G. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates. Hum Reprod. 2006;21:2645–9.PubMed
32.
O’dea L, O’brien F, Currie K, Hemsey G. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008;24:2785–93.PubMed
33.
Shoham Z, Smith H, Yeko T, O’brien F, Hemsey G, O’dea L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol. 2008;69:471–8.
34.
Kaufmann R, Dunn R, Vaughn T, Hughes G, O’brien F, Hemsey G, O’dea LSL. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotropin-deficient women. Clin Endocrinol. 2007;67:563–9.
35.
Schoot DC, Harlin J, Shoham Z, Mannaerts B, Lahlou N, Bouchard P, Bennink H, Fauser B. Recombinant human follicle-stimulating-hormone and ovarian response in gonadotropin-deficient women. Hum Reprod. 1994;9:1237–42.PubMed
36.
Couzinet B, Lestrat N, Brailly S, Forest M, Schaison G. Stimulation of ovarian follicular maturation with pure follicle-stimulating-hormone in women with gonadotropin-deficiency. J Clin Endocrinol Metab. 1988;66:552–6.PubMed
37.
Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril. 2009;91:749–66.PubMed
38.
Venetis CA, Kolibianakis EM, Tarlatzi TB, Tarlatzis BC. Evidence-based management of poor ovarian response. Ann N Y Acad Sci. 2010;1205:199–206.PubMed
39.
Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2009;15:613–22.PubMed
40.
Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997;104:521–7.PubMed
41.
Kailasam C, Keay SD, Wilson P, Ford WC, Jenkins JM. Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome. Hum Reprod. 2004;19:1544–7.PubMed
42.
Lehert P, Kolibianakis EM, Venetis CA, Schertz J, Saunders H, Arriagada P, Copt S, Tarlatzis B. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol. 2014;12:17.PubMedPubMedCentral
43.
Ulug U, Ben-Shlomo I, Turan E, Erden HF, Akman MA, Bahceci M. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod Biomed Online. 2003;6:439–43.PubMed
44.
Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400,135 treatment cycles. Hum Reprod. 2011;26:1768–74.PubMed
45.
Hughes EG, Fedorkow DM, Daya S. The routine use of gonadotropin releasing hormone agonists prior to in-vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 1992;58:888–96.PubMed
46.
Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev. 2000;2:CD001299.
47.
Garcia J, Padilla S, Bayati J, Baramki T. Follicular phase gonadotropin—releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril. 1990;53:302–5.PubMed
48.
Kenigsberg D, Littman BA, Hodgen GD. Medical hypophysectomy. I. Dose- response using a gonadotropin-releasing hormone antagonist. Fertil Steril. 1984;42:112–5.PubMed
49.
Huirne JA, Lambalk CB. Gonadotropin—releasing-hormone-receptor antagonists. Lancet. 2001;358:1793–803.PubMed
50.
Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15:1490–8.PubMed
51.
Matikainen T, Ding YQ, Vergara M, Huhtaniemi I, Couzinet B, Schaison G. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin—releasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol Metab. 1992;75:820–5.PubMed
52.
Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod. 2000;15:1965–8.PubMed
53.
Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:CD001750.
54.
Grow D, Kawwass JF, Kulkarni AD, Durant T, Jamieson DJ, Macaluso M. GnRH agonist and GnRH antagonist protocols: comparison of outcomes among good-prognosis patients using national surveillance data. Reprod Biomed Online. 2014;29:299–304.PubMed
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
